Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
J Natl Compr Canc Netw
; 20(4): 322-334, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390768
2.
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Blood
; 134(7): 606-613, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186274
3.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(6): 755-781, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502987
4.
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
J Natl Compr Canc Netw
; 16(3): 245-254, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523663
5.
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Blood
; 125(9): 1394-402, 2015 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25573987
6.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(5): 608-638, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476741
7.
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood
; 123(22): 3390-7, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615777
8.
Hodgkin lymphoma, version 2.2015.
J Natl Compr Canc Netw
; 13(5): 554-86, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25964641
9.
Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
Ann Hematol
; 93(8): 1305-12, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24590536
10.
Follicular lymphoma with progression to diffuse large B-cell lymphoma and concurrent CD5-negative mantle cell lymphoma-3 entities in a lymph node.
Cancer Control
; 21(3): 251-4, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24955711
11.
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis.
Clin Lymphoma Myeloma Leuk
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38508880
12.
Autologous hematopoietic cell transplantation consolidation for first response is associated with longer survival among patients with nodal peripheral T-cell lymphoma.
Transplant Cell Ther
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740140
13.
Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population.
Clin Lymphoma Myeloma Leuk
; 23(8): 606-609, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210271
14.
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Blood Adv
; 7(7): 1130-1136, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053786
15.
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
J Natl Compr Canc Netw
; 10(5): 589-97, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22570290
16.
Follicular lymphoma: current management and future directions.
Cancer Control
; 19(3): 187-95, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22710894
17.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
J Hematol Oncol
; 15(1): 96, 2022 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35842643
18.
Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Clin Lymphoma Myeloma Leuk
; 21(2): 132-138, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32950461
19.
Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma.
Ann Hematol
; 94(2): 357-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034876
20.
High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.
Clin Lymphoma Myeloma Leuk
; 19(9): e513-e520, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31253594